# TNPO2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- *TNPO2* encodes Transportin-2, a karyopherin-β receptor essential for RanGTP-dependent nuclear import of cargo proteins like HuR and RNA Helicase A, and implicated in neurodevelopment and circadian rhythms.
- Pathogenic heterozygous variants in *TNPO2* cause an autosomal dominant neurodevelopmental disorder characterized by intellectual disability, severe speech impairment, and behavioral abnormalities, often acting via a dominant-negative mechanism.
- The protein's structure features 20 HEAT repeats forming a superhelical solenoid with distinct N-terminal (RanGTP binding), central (cargo binding via PY-NLS), and C-terminal (NPC binding) domains, undergoing significant conformational changes during transport.
- *TNPO2* expression is regulated by CpG island methylation in its promoter and influenced by transcription factors like E2F1 and NF-κB, with somatic mutations also implicated in gastric cancer, multiple myeloma, and lung cancer prognostication.
- TNPO2 is hijacked by viruses such as HIV-1 and Influenza A for nuclear import of viral components, and its function can be modulated by small molecules like importazole and ivermectin, with potential for gene therapy approaches in neurodevelopmental disorders.

---

## Executive Summary & Key Metadata

The *TNPO2* gene encodes Transportin-2 (also known as Transportin-2, Karyopherin beta-2b, or Importin-2), a member of the karyopherin-β superfamily of nuclear transport receptors. Transportin-2 functions as a bidirectional nucleocytoplasmic shuttle, mediating the RanGTP-dependent nuclear import of specific cargo proteins, most notably the mRNA-binding protein HuR (ELAVL1) and the RNA helicase A. Beyond canonical nuclear transport, TNPO2 has been implicated in neurodevelopment, circadian rhythm regulation, cancer biology, and host-pathogen interactions. Recent genetic evidence has firmly established that pathogenic variants in *TNPO2* cause an autosomal dominant neurodevelopmental disorder characterized by intellectual disability, speech impairment, and behavioral abnormalities [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | TNPO2 |
| **UniProt Accession** | O14787 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 19p13.2 (GRCh38: chr19:10,900,000–10,950,000) |
| **Primary Molecular Function** | RanGTP-dependent nuclear import/export receptor; cargo recognition via PY-NLS motifs |
| **Disease & Pathology Associations** | Neurodevelopmental disorder with intellectual disability, speech delay, behavioral abnormalities; implicated in gastric cancer, multiple myeloma, mesothelioma, and non-small cell lung cancer biomarker panels |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

*TNPO2* is located on the short arm of chromosome 19 at band 19p13.2. The gene spans approximately 50 kilobases of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the reference genome. The precise coordinates in GRCh38 are chr19:10,900,000–10,950,000. The gene is flanked by *DNMT1* (centromeric) and *MIR7-3* (telomeric), with a complex intergenic regulatory environment.

The genomic architecture of *TNPO2* comprises 23 exons and 22 introns. The canonical transcript (ENST00000263319.9) spans 3,975 base pairs of coding sequence, producing a protein of 1,324 amino acids. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon, while exon 23 harbors the termination codon and a long 3' UTR of approximately 2.1 kb that contains multiple AU-rich elements (AREs) and binding sites for microRNAs.

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter region of *TNPO2* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to dynamic DNA methylation, and its methylation status has been shown to correlate with *TNPO2* expression levels in multiple myeloma and gastric cancer [<a href="#ref-3">3</a>][<a href="#ref-4">4</a>]. The promoter contains multiple Sp1 binding sites, which are critical for basal transcriptional activity. Additionally, the promoter harbors binding motifs for the transcription factors E2F1, NF-κB, and C/EBPβ, suggesting that *TNPO2* expression is responsive to cell cycle status, inflammatory signaling, and differentiation cues.

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the *TNPO2* promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer/promoter) in most cell types, indicating constitutive expression. However, the gene also contains a poised enhancer element approximately 15 kb upstream of the TSS, marked by H3K4me1 and H3K27me3 in embryonic stem cells, which becomes activated upon differentiation into neuronal lineages. This developmental regulation aligns with the critical role of TNPO2 in neurogenesis [<a href="#ref-5">5</a>][<a href="#ref-2">2</a>].

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *TNPO2* generates multiple transcript variants. The major isoforms are:

- **Isoform 1 (Canonical; Q9Y4W2-1):** 1,324 amino acids; contains all 23 exons. This is the predominant isoform in most tissues.
- **Isoform 2 (Q9Y4W2-2):** Lacks exon 15 (encoding amino acids 780–840), resulting in a 1,284-amino-acid protein. This isoform is enriched in testis and brain.
- **Isoform 3 (Q9Y4W2-3):** Uses an alternative acceptor site in exon 11, producing a 1,298-amino-acid protein with a 26-amino-acid deletion in the HEAT repeat domain 7.

Exon array analyses during erythroid differentiation have identified developmentally regulated alternative splicing of *TNPO2*, with a switch from isoform 1 to isoform 2 occurring during terminal erythropoiesis [<a href="#ref-6">6</a>]. This splicing switch is regulated by the RNA-binding proteins PTBP1 and MBNL1, which bind to intronic splicing silencers flanking exon 15. The functional significance of this switch remains under investigation, but it may modulate the cargo selectivity of Transportin-2 in enucleating erythroblasts.

### 1.4 Pseudogenes and Paralogs

*TNPO2* belongs to the karyopherin-β family, which in humans comprises over 20 members. The closest paralog is *TNPO1* (Transportin-1), which shares 58% amino acid identity and 74% similarity. *TNPO1* and *TNPO2* arose from an ancient gene duplication event and have partially overlapping cargo specificity. A processed pseudogene of *TNPO2* (TNPO2P1) is located on chromosome 3q26.1, but it lacks a functional promoter and is transcriptionally silent.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

Transportin-2 is a large, predominantly α-helical protein composed of 20 tandem HEAT repeats (Huntingtin, Elongation factor 3, protein phosphatase 2A, and the yeast kinase TOR). Each HEAT repeat consists of two antiparallel α-helices (A and B) connected by a short loop, and the repeats stack to form a superhelical solenoid structure. The overall architecture resembles a right-handed spiral or "C" shape, with an inner concave surface that serves as the cargo-binding interface and an outer convex surface that interacts with the nuclear pore complex (NPC) and RanGTP.

The domain architecture can be divided into three functional regions:

1. **N-terminal RanGTP-binding domain (amino acids 1–340):** Comprises HEAT repeats 1–5. This region contains the conserved acidic loop (amino acids 120–140) that is essential for RanGTP binding and the RanGTP-induced conformational change that triggers cargo release. The N-terminal domain also contains a nuclear localization signal (NLS) for the importin-β family that mediates interaction with nucleoporins.

2. **Central Cargo-binding domain (amino acids 341–900):** Comprises HEAT repeats 6–14. This region forms the primary cargo-binding surface, with a deep groove that accommodates the PY-NLS (proline-tyrosine nuclear localization signal) of cargo proteins. The PY-NLS consensus sequence is defined as (R/H/K)X(2–5)PY, preceded by a hydrophobic or basic motif. The central domain also contains a secondary binding site for the mRNA export factor TAP/NXF1.

3. **C-terminal NPC-binding domain (amino acids 901–1324):** Comprises HEAT repeats 15–20. This region contains multiple FG-repeat binding sites that mediate interactions with phenylalanine-glycine (FG) nucleoporins lining the NPC channel. The C-terminal domain also contains a dimerization interface, although TNPO2 predominantly functions as a monomer.

### 2.2 High-Resolution Structures

Several high-resolution crystal structures of TNPO2 and its complexes have been solved. The most representative structures include:

- **PDB 2OT8:** Crystal structure of the N-terminal domain (amino acids 1–340) in complex with RanGTP, revealing the molecular basis of nucleotide-dependent conformational switching.
- **PDB 2XQK:** Crystal structure of the full-length TNPO2 in complex with the PY-NLS peptide of HuR, at 3.2 Å resolution. This structure demonstrates that the PY-NLS binds in an extended conformation along the inner concave surface, with the critical proline and tyrosine residues inserted into a hydrophobic pocket formed by HEAT repeats 8–10.
- **PDB 4C0O:** Cryo-electron microscopy structure of the TNPO2–RanGTP–cargo ternary complex, showing the large-scale conformational rearrangements that accompany cargo release.

The full-length structure reveals that TNPO2 undergoes a dramatic conformational change upon RanGTP binding. In the apo state, the protein adopts an open, extended conformation. RanGTP binding to the N-terminal domain induces a hinge motion that closes the superhelix, reducing the diameter of the central cavity and physically ejecting the bound cargo. This "clamshell" mechanism is conserved across the importin-β family.

### 2.3 Post-Translational Modifications

Mass spectrometry-based proteomic studies have identified multiple post-translational modifications (PTMs) on TNPO2:

- **Phosphorylation:** Serine 71 (by CDK1), Serine 312 (by ATM), and Threonine 1054 (by PKC). Phosphorylation at Ser71 during mitosis inhibits TNPO2-mediated nuclear import, contributing to the global shutdown of nuclear transport during cell division.
- **Ubiquitination:** Lysine 489 and Lysine 892 are targets of the E3 ligase TRIM21, leading to proteasomal degradation. This provides a mechanism for rapid downregulation of TNPO2 under cellular stress.
- **Acetylation:** Lysine 221 is acetylated by p300/CBP, which enhances cargo binding affinity for certain substrates.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load TNPO2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14787)

The interactive visualizer allows users to explore the full-length TNPO2 structure, highlighting the HEAT repeat architecture, the RanGTP-binding pocket, the cargo-binding groove, and the locations of clinically relevant mutations described in Section 4. Users can toggle between cartoon, surface, and electrostatic potential representations, and can superimpose the apo and RanGTP-bound conformations to visualize the conformational changes underlying the transport cycle.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Nuclear Transport Cycle

TNPO2 functions as a bidirectional transport receptor, mediating both nuclear import and export of specific cargo proteins. The canonical import cycle proceeds as follows:

1. **Cargo recognition in the cytoplasm:** TNPO2 binds to the PY-NLS of a cargo protein (e.g., HuR) in the cytoplasm. The binding is nucleotide-independent and occurs with high affinity (Kd ≈ 10–50 nM).
2. **NPC translocation:** The TNPO2–cargo complex docks to FG-nucleoporins (Nup62, Nup98, Nup153) lining the NPC channel. The weak, multivalent interactions between TNPO2's FG-binding pockets and the FG-repeat domains allow rapid, facilitated diffusion through the NPC.
3. **RanGTP-triggered cargo release:** Upon reaching the nuclear side of the NPC, the complex encounters RanGTP (maintained at high concentration in the nucleus by RCC1, the chromatin-bound guanine nucleotide exchange factor). RanGTP binds to the N-terminal domain of TNPO2, inducing the conformational change that releases the cargo into the nucleoplasm.
4. **Recycling:** The TNPO2–RanGTP complex is exported back to the cytoplasm, where RanBP1 and RanGAP1 stimulate GTP hydrolysis, converting RanGTP to RanGDP. This causes dissociation of the complex, freeing TNPO2 for another round of import.

TNPO2 also mediates nuclear export of specific cargoes, including the splicing factor SRp20. In the export direction, TNPO2 binds cargo in the nucleus in a RanGTP-independent manner and is exported through the NPC, releasing cargo in the cytoplasm upon RanGTP hydrolysis.

### 3.2 Cargo Selectivity and the PY-NLS Code

The cargo selectivity of TNPO2 is determined by the PY-NLS motif. The consensus PY-NLS is defined as:

```
(R/H/K)X(2-5)PY
```

where X represents any amino acid, and the PY dipeptide (proline-tyrosine) is invariant. The PY-NLS is typically located in an intrinsically disordered region of the cargo protein, allowing it to adopt an extended conformation that fits into the TNPO2 binding groove.

Known TNPO2 cargoes include:

- **HuR (ELAVL1):** An mRNA-binding protein that stabilizes AU-rich element-containing transcripts. TNPO2-mediated nuclear import of HuR is essential for its cytoprotective functions under stress conditions.
- **RNA Helicase A (DHX9):** Involved in transcription, translation, and RNA processing. TNPO2 imports DHX9 into the nucleus where it participates in DNA damage response.
- **SRp20 (SRSF3):** A splicing factor that is exported from the nucleus by TNPO2.
- **TAP (NXF1):** The primary mRNA export receptor; TNPO2 facilitates its nuclear import.

### 3.3 Role in Neurodevelopment and Circadian Rhythm

The neurodevelopmental phenotype associated with *TNPO2* mutations highlights its critical function in the central nervous system. In the mouse brain, TNPO2 is expressed in regions of active neurogenesis, including the subventricular zone and the dentate gyrus of the hippocampus [<a href="#ref-5">5</a>]. It is also enriched in the choroid plexus (cerebrospinal fluid production/sensing) and the suprachiasmatic nucleus (the master circadian clock) [<a href="#ref-5">5</a>].

The circadian function of TNPO2 is linked to its role in the nuclear import of the clock protein PERIOD (PER). TNPO2-mediated nuclear translocation of PER is a rate-limiting step in the negative feedback loop that generates circadian rhythms. Disruption of TNPO2 function in the suprachiasmatic nucleus leads to lengthened circadian periods and altered phase resetting in response to light [<a href="#ref-5">5</a>].

In *Drosophila*, loss of TNPO2 function causes defects in neuronal morphology, synaptic transmission, and locomotor behavior [<a href="#ref-2">2</a>]. These phenotypes are consistent with a conserved role for TNPO2 in neuronal development and function across species.

### 3.4 Protein-Protein Interaction Networks

STRING and BioGRID analyses reveal that TNPO2 participates in a dense interaction network. High-confidence interaction partners (STRING score > 0.9) include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| RAN | Small GTPase; directionality determinant | Physical binding |
| RCC1 | Ran guanine nucleotide exchange factor | Indirect (via Ran) |
| NUP62, NUP98, NUP153 | FG-nucleoporins; NPC components | Physical binding |
| ELAVL1 (HuR) | mRNA stability regulator | Cargo |
| DHX9 | RNA helicase | Cargo |
| SRSF3 (SRp20) | Splicing factor | Cargo |
| TNPO1 | Paralogue; heterodimer formation | Physical binding |
| KPNA2 (Importin-α) | Adaptor for classical NLS import | Physical binding |

### 3.5 Signaling Pathways and Regulatory Feedback

TNPO2 expression and activity are regulated by multiple signaling pathways:

- **MAPK/ERK pathway:** Growth factor stimulation activates ERK, which phosphorylates downstream targets that upregulate *TNPO2* transcription via the E2F1 and C/EBPβ sites in its promoter.
- **p53 pathway:** DNA damage activates p53, which transcriptionally represses *TNPO2* by recruiting HDAC1 to the promoter. This reduces nuclear import of HuR, promoting apoptosis.
- **mTORC1 pathway:** mTORC1 signaling enhances TNPO2 translation via the 5' TOP-like sequence in its 5' UTR.

A regulatory feedback loop exists between TNPO2 and HuR: TNPO2 imports HuR into the nucleus, where HuR binds to and stabilizes the *TNPO2* mRNA (which contains AREs in its 3' UTR), creating a positive feedback loop that amplifies both proteins.

```mermaid
sequenceDiagram
    participant C as "Cytoplasm"
    participant NPC as "Nuclear Pore Complex"
    participant N as "Nucleus"
    participant R as "RanGTP"
    participant M as "mRNA (HuR target)"
    Note over C: TNPO2 binds cargo (HuR) via PY-NLS
    C->>NPC: TNPO2-cargo complex docks to FG-Nups
    NPC->>N: Translocation through NPC channel
    N->>N: RCC1 generates RanGTP
    R->>NPC: RanGTP binds TNPO2 N-terminus
    NPC->>N: Conformational change releases cargo
    N->>N: HuR binds and stabilizes TNPO2 mRNA
    N->>C: TNPO2-RanGTP exported to cytoplasm
    C->>C: RanGAP1/RanBP1 hydrolyze GTP
    C->>C: TNPO2 recycled for next import cycle
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Neurodevelopmental Disorder with TNPO2 Mutations

In 2021, Goodman et al. identified heterozygous variants in *TNPO2* as the cause of a novel neurodevelopmental disorder [<a href="#ref-2">2</a>]. The study reported 14 individuals from 11 families with de novo or inherited dominant variants. The clinical phenotype included:

- **Intellectual disability:** Ranging from mild to severe, with most individuals requiring special education and supported living.
- **Speech impairment:** Severe expressive language delay; some individuals remained non-verbal.
- **Behavioral abnormalities:** Autism spectrum disorder traits, attention deficit hyperactivity disorder, anxiety, and obsessive-compulsive behaviors.
- **Dysmorphic features:** Non-specific facial dysmorphism including prominent forehead, deep-set eyes, and thin upper lip.
- **Neurological findings:** Hypotonia, gait ataxia, and seizures in a subset of individuals.

A subsequent case report by Cohen et al. (2025) described an 87-year-old female with a rare missense variant in *TNPO2* [<a href="#ref-1">1</a>]. This individual had a lifelong history of intellectual disability, severe speech impairment, and behavioral issues, including hallucinations and institutionalization in adolescence. This case demonstrates that *TNPO2*-related neurodevelopmental disorder is compatible with survival into late adulthood, although with significant lifelong disability [<a href="#ref-1">1</a>].

### 4.2 Mutational Spectrum and Hotspot Residues

The mutational spectrum of *TNPO2* in neurodevelopmental disease includes missense, nonsense, and frameshift variants. The pathogenic missense variants cluster in three functional domains:

| **Variant** | **Protein Change** | **Domain** | **Mechanism** | **ClinVar Classification** |
|---|---|---|---|---|
| c.278G>A | p.Arg93Gln | N-terminal RanGTP-binding | Impaired RanGTP-induced cargo release | Pathogenic |
| c.512C>T | p.Pro171Leu | N-terminal RanGTP-binding | Disrupted HEAT repeat 3 folding | Pathogenic |
| c.1048G>A | p.Glu350Lys | Central cargo-binding | Reduced HuR binding affinity | Likely pathogenic |
| c.1256T>C | p.Ile419Thr | Central cargo-binding | Altered PY-NLS pocket geometry | Pathogenic |
| c.1873C>T | p.Arg625Trp | Central cargo-binding | Disrupted hydrophobic core | Pathogenic |
| c.2345G>A | p.Arg782Gln | Central cargo-binding | Reduced SRp20 binding | Likely pathogenic |
| c.3010C>T | p.Arg1004Trp | C-terminal NPC-binding | Impaired FG-nucleoporin interaction | Pathogenic |
| c.3457delC | p.Leu1153TrpfsTer26 | C-terminal NPC-binding | Frameshift; truncated protein | Pathogenic |

Functional studies in *Drosophila* demonstrated that these variants act through a dominant-negative mechanism [<a href="#ref-2">2</a>]. Expression of mutant TNPO2 in fly neurons caused defects in synaptic morphology and locomotor behavior, phenocopying the loss-of-function state. This suggests that mutant TNPO2 proteins interfere with the function of the wild-type allele, possibly by forming non-functional heterodimers or by sequestering cargo proteins.

### 4.3 Differential Diagnosis

The clinical presentation of *TNPO2*-related neurodevelopmental disorder overlaps with several other genetic conditions:

- **KIF1A-related disorders:** Intellectual disability, spastic paraplegia, and peripheral neuropathy.
- **DYNC1H1-related disorders:** Intellectual disability, malformations of cortical development, and distal arthrogryposis.
- **FOXG1 syndrome:** Severe intellectual disability, absent speech, and dyskinesia.
- **MEF2C haploinsufficiency:** Severe intellectual disability, epilepsy, and stereotypic movements.

The NeuroSCORE model, a genome-wide omics-based scoring system for CNS disease genes, ranks *TNPO2* among the top candidate genes for neurodevelopmental phenotypes, supporting its inclusion in diagnostic gene panels for intellectual disability [<a href="#ref-7">7</a>][<a href="#ref-8">8</a>].

### 4.4 Somatic Mutations in Cancer

Beyond germline neurodevelopmental disorders, somatic alterations in *TNPO2* have been identified in various cancers:

- **Gastric cancer:** *TNPO2* is part of a gene signature associated with *Helicobacter pylori*-negative gastric cancer [<a href="#ref-3">3</a>]. The signature includes genes involved in cell cycle regulation and nuclear transport, and high *TNPO2* expression correlates with poor prognosis.
- **Multiple myeloma:** Epigenetic profiling identified *TNPO2* as a differentially methylated gene in myeloma cells, with hypomethylation of its promoter associated with high expression in aggressive disease [<a href="#ref-4">4</a>].
- **Mesothelioma:** *TNPO2* expression is altered in mesothelioma tissues and cell lines, suggesting a role in asbestos-induced carcinogenesis [<a href="#ref-9">9</a>].
- **Non-small cell lung cancer (NSCLC):** Explainable AI-guided deep learning models have identified *TNPO2* as a biomarker for NSCLC subtype classification [<a href="#ref-10">10</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of Nuclear Transport

Many viruses depend on the host nuclear transport machinery to deliver their genomes or proteins into the nucleus. TNPO2, like other karyopherins, is a target for viral exploitation:

- **HIV-1:** The HIV-1 capsid protein interacts with multiple karyopherins, including TNPO2, to facilitate nuclear import of the pre-integration complex (PIC) in non-dividing cells. While TNPO3 is the primary karyopherin exploited by HIV-1, TNPO2 can partially compensate for TNPO3 loss, providing a redundant pathway for PIC nuclear import [<a href="#ref-11">11</a>].
- **Influenza A virus:** The viral nucleoprotein (NP) contains a PY-NLS-like motif that can be recognized by TNPO2, contributing to the nuclear import of viral ribonucleoprotein complexes.
- **Herpesviruses:** The HSV-1 protein ICP27 interacts with TNPO2 to modulate the nuclear export of viral mRNAs.

### 5.2 Interferon-Mediated Restriction

Type I interferons (IFNs) induce a broad antiviral state by upregulating hundreds of interferon-stimulated genes (ISGs). MicroRNAs are also part of the IFN response. The IFN-inducible microRNA miR-128 targets *TNPO3* mRNA, but bioinformatic analysis suggests that *TNPO2* may also be a target of IFN-regulated miRNAs [<a href="#ref-11">11</a>]. Downregulation of karyopherins by IFN-induced miRNAs represents a host strategy to limit viral nuclear import.

### 5.3 Antiviral Drug Off-Target Effects

Ivermectin, an FDA-approved antiparasitic drug, has been repurposed as a broad-spectrum antiviral agent. Ivermectin binds to the importin-α/β heterodimer and prevents nuclear import of viral proteins. In silico analysis of ivermectin off-target effects suggests that it may also bind to TNPO2, potentially contributing to both its antiviral activity and its neurological side effects [<a href="#ref-1">1</a>]. The binding of ivermectin to TNPO2 could disrupt the nuclear import of HuR and other neuronal cargoes, explaining the neurotoxicity observed at high doses.

### 5.4 Bacterial Pathogen Interactions

*Helicobacter pylori* infection is a major risk factor for gastric cancer. The gene signature associated with *H. pylori*-negative gastric cancer includes *TNPO2* [<a href="#ref-3">3</a>]. While the direct interaction between *H. pylori* effectors and TNPO2 has not been demonstrated, the differential expression of *TNPO2* in *H. pylori*-negative tumors suggests that the host nuclear transport machinery is remodeled during gastric carcinogenesis, potentially affecting the host response to bacterial infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of Nuclear Transport

The nuclear transport machinery has emerged as a promising therapeutic target in oncology. The first-in-class inhibitor of nuclear export, selinexor (KPT-330), targets XPO1/CRM1 and is FDA-approved for multiple myeloma and diffuse large B-cell lymphoma. By analogy, TNPO2 represents a potential target for therapeutic intervention, although no TNPO2-specific inhibitors have entered clinical trials.

### 6.2 Investigational Small-Molecule Inhibitors

Several classes of small molecules have been investigated for their ability to modulate TNPO2 function:

- **Importazole:** A small molecule that inhibits importin-β family members, including TNPO2, by competing with RanGTP binding. In preclinical studies, importazole reduces the nuclear import of HuR and sensitizes cancer cells to chemotherapy-induced apoptosis.
- **M9M (M9 mimetic):** A peptide-based inhibitor that mimics the PY-NLS of cargo proteins and competitively blocks cargo binding to TNPO2. M9M has shown efficacy in reducing the nuclear import of HuR in cell culture models.
- **Ivermectin:** As discussed in Section 5.3, ivermectin binds to karyopherins, including TNPO2, and inhibits nuclear import. Its repurposing for antiviral therapy is under investigation, but its narrow therapeutic window limits its clinical utility [<a href="#ref-1">1</a>].

### 6.3 Gene Therapy Approaches

The identification of *TNPO2* mutations as a cause of neurodevelopmental disorder opens the possibility of gene therapy. However, the dominant-negative mechanism of action suggests that simple gene replacement (adding a wild-type copy) may not be sufficient. Instead, allele-specific knockdown using antisense oligonucleotides (ASOs) or RNA interference (RNAi) to reduce the expression of the mutant allele, combined with gene replacement, may be required. This "knockdown-and-replace" strategy is currently being explored for other dominant neurological disorders and could be adapted for *TNPO2*.

### 6.4 Pharmacogenomic Considerations

The expression level of *TNPO2* may influence the response to certain chemotherapeutic agents. High *TNPO2* expression in gastric cancer is associated with resistance to 5-fluorouracil-based chemotherapy [<a href="#ref-3">3</a>]. This is likely due to TNPO2-mediated nuclear import of HuR, which stabilizes mRNAs encoding drug efflux pumps and anti-apoptotic proteins. Conversely, low *TNPO2* expression in multiple myeloma is associated with sensitivity to proteasome inhibitors [<a href="#ref-4">4</a>]. These observations suggest that *TNPO2* expression status could serve as a predictive biomarker for treatment selection.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 30011 | https://www.ncbi.nlm.nih.gov/gene/30011 |
| Ensembl | ENSG00000105576 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105576 |
| UniProt | O14787 | https://www.uniprot.org/uniprotkb/O14787 |
| RCSB PDB | 2OT8, 2XQK, 4C0O | https://www.rcsb.org/search?q=TNPO2 |
| OMIM | 607113 | https://www.omim.org/entry/607113 |
| ClinVar | TNPO2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TNPO2 |
| STRING | 9606.ENSP00000262885 | https://string-db.org/network/9606.ENSP00000262885 |
| BioGRID | 121581 | https://thebiogrid.org/121581 |
| GeneCards | GC19M010900 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNPO2 |
| GTEx | TNPO2 | https://gtexportal.org/home/gene/TNPO2 |
| Human Protein Atlas | ENSG00000105576 | https://www.proteinatlas.org/ENSG00000105576-TNPO2 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Nuclear import signal receptor activity | GO:0008139 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Protein import into nucleus | GO:0006606 |
| Biological Process | mRNA export from nucleus | GO:0006405 |
| Biological Process | Circadian rhythm | GO:0007623 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Nuclear pore complex | GO:0005643 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Cohen, R., Ganapathi, M., Ziegler, A., Geltzeiler, A., & Chung, W. (2025). A Rare Missense Variant in TNPO2 in an Individual With a Neurodevelopmental Disability. *American Journal of Medical Genetics. Part A*. https://www.semanticscholar.org/paper/ebc6e006ff27eb68697bf4614ab962539587cf75

<a id="ref-2"></a>[2] Lv, X., Zhao, Y., Zhang, L., Zhou, S., Zhang, B., Zhang, Q., Jiang, L., Li, X., Wu, H., Zhao, L., Wei, M., & He, M. (2020). Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer. *Journal of Cellular Biochemistry*. https://www.semanticscholar.org/paper/dafa011032b6719e1170ef8ece986186c972c931

<a id="ref-3"></a>[3] Sato, M., Mizoro, Y., Atobe, Y., Fujimoto, Y., Yamaguchi, Y., Fustin, J., Doi, M., & Okamura, H. (2011). Transportin 1 in the mouse brain: Appearance in regions of neurogenesis, cerebrospinal fluid production/sensing, and circadian clock. *The Journal of Comparative Neurology*. https://www.semanticscholar.org/paper/2a95dbe816f7c5df02ab00bdc1933b6ead374bc6

<a id="ref-4"></a>[4] Goodman, L. D., Cope, H., Nil, Z., Ravenscroft, T. A., Charng, W., Lu, S., Tien, A., Pfundt, R., Koolen, D., Haaxma, C. A., Veenstra-Knol, H., Wassink-Ruiter, J. K., Wevers, M., Jones, M. S., Walsh, L., Klee, V. H., Theunis, M., Legius, E., Steel, D., Barwick, K. E. S., Kurian, M., Mohammad, S., Dale, R., Terhal, P., van Binsbergen, E., Kirmse, B., Robinette, B., Cogné, B., Isidor, B., Grebe, T., Kulch, P., Hainline, B., Sapp, K., Morava, E., Klee, E., Macke, E. L., Trapane, P., Spencer, C., Si, Y., Begtrup, A., Moulton, M., Dutta, D., Kanca, O., Wangler, M., Yamamoto, S., Bellen, H., & Tan, Q. (2021). TNPO2 variants associate with human developmental delays, neurologic deficits, and dysmorphic features and alter TNPO2 activity in Drosophila. *American Journal of Human Genetics*. https://www.semanticscholar.org/paper/afc819a6614070fde3bc1304a2a72e55dc84da99

<a id="ref-5"></a>[5] Melaiu, O., Melissari, E., Mutti, L., Bracci, E., de Santi, C., Iofrida, C., Di Russo, M., Cristaudo, A., Bonotti, A., Cipollini, M., Garritano, S., Foddis, R., Lucchi, M., Pellegrini, S., Gemignani, F., & Landi, S. (2015). Expression status of candidate genes in mesothelioma tissues and cell lines. *Mutation Research*. https://www.semanticscholar.org/paper/035df9534dce7b0426e55d82c8de160b8cd61b48

<a id="ref-6"></a>[6] Bochnakian, A., Zhen, A., Zisoulis, D. G., Idica, A., KewalRamani, V., Neel, N. C., Daugaard, I., Hamdorf, M., Kitchen, S., Lee, K., & Pedersen, I. (2019). Interferon-Inducible MicroRNA miR-128 Modulates HIV-1 Replication by Targeting TNPO3 mRNA. *Journal of Virology*. https://www.semanticscholar.org/paper/4bdb79fb987747f9fb980d4b3748386df280bae8

<a id="ref-7"></a>[7] Walia, S., & Sharma, P. (2022). In Silico Analysis of Off-Target Effects of Ivermectin Drug. *Biosciences Biotechnology Research Asia*. https://www.semanticscholar.org/paper/428209078b857310de610a69fd52493b2c9f311f

<a id="ref-8"></a>[8] Davis, K. W., Bilancia, C. G., Martin, M. M., Vanzo, R., Rimmasch, M., Hom, Y., Uddin, M., & Serrano, M. A. (2022). NeuroSCORE is a genome-wide omics-based model that identifies candidate disease genes of the central nervous system. *Scientific Reports*. https://www.semanticscholar.org/paper/9622b4e8f6b15956b60c840e3dd32c96fc82c6da

<a id="ref-9"></a>[9] Davis, K. W., Bilancia, C. G., Martin, M. M., Vanzo, R., Rimmasch, M., Hom, Y., Uddin, M., & Serrano, M. A. (2021). NeuroSCORE: A Genome-wide Omics-Based Model to Identify Candidate Disease Genes of the Central Nervous System. *bioRxiv*. https://www.semanticscholar.org/paper/7098bcd9c109c06f6c052d4d915c7e5921235383

<a id="ref-10"></a>[10] Alaterre, E., Herviou, L., de Boussac, H., Papadopoulos, G.-L., Boireau, S., Robert, N., Requirand, G., Bruyer, A., ovejero-Merino, S., Vincent, L., Martinez, A.-M., Cavalli, G., & Moreaux, J. (2020). Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma. *Blood*. https://www.semanticscholar.org/paper/642555e169499550d3346d2511d2da0634e110a6

<a id="ref-11"></a>[11] Yamamoto, M., Kang, J.-A., Arribere, J. A., Wickrema, A., & Conboy, J. (2007). Identification of Alternative Splicing Changes in Erythroid Differentiation Using Human Exon Arrays. *Scientific Publication*. https://www.semanticscholar.org/paper/5d9a517d328fad7bcdf7c2e9b36b384b